BioSpace News Archive

electroCore, Inc.today announced that it has agreed to issue and sell to certain institutional and accredited investors an aggregate of 1,675,914 registered shares of common stock (or common stock equivalents) and unregistered warrants to purchase up to an aggregate of 837,955 shares of common stock.

AppYea Inc., which is focused on the development of accurate wearable monitoring solutions to treat sleep apnea and snoring, announced the appointment of Adi Shemer as Chief Executive Officer of the Company.

The Lupus Foundation of America announces five recipients of the 2023 Gina M. Finzi Memorial Student Summer Fellowship Program.

Seegene Inc., a leading South Korean company providing a total solution for PCR molecular diagnostics, took part in the 2023 American Association of Clinical Chemistry Annual Scientific Meeting & Clinical Lab Expo in California between July 25-27.

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination with carboplatin and paclitaxel, followed by Jemperli as a single agent for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR), as determined by an FDA-approved test, or microsatellite instability-high (MSI-H).

MannKind Corporation will release its 2023 second quarter financial results and year to date financial results and its management will host a conference call to discuss these results and corporate updates at 5:00 PM on Monday, August 7, 2023.

Galecto, Inc., a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, announced its operating and financial results for the quarter ended June 30, 2023.

Codexis, Inc., a leading enzyme engineering company, announced the launch of a new mini documentary as part of an ongoing campaign in support of World Health Day.

Emergent BioSolutions Inc. announced that it was awarded a 10-year contract by the BARDA, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, valued at up to a maximum of $704 million, for advanced development, manufacturing scale-up, and procurement of Ebanga™, a licensed treatment for Ebola virus disease.

Replimune Group, Inc. (NASDAQ:REPL) and Incyte today announced a clinical trial collaboration and supply agreement to study RP1, Replimune’s lead product candidate, in combination with INCB99280, Incyte’s small molecule oral PD-L1 inhibitor.